BRAF and melanoma: The zoledronic acid + GSK126 association exerted a strong anti-proliferative effect on BRAF-mutant, NRAS-mutant, and BRAF/NRAS wild-type melanoma cell lines (Fig. 7b), compared to treatment with single agents, and induced significant apoptosis on BRAF wild-type melanoma cell lines (Fig. 7c).